Each module will include a moderated slide presentation reviewing key publications, presentations and ongoing trials in addition to a clinical decision-making track facilitated through the use of networked tablet technology. All events will take place from 8:00 AM to 4:00 PM (breakfast and lunch buffets to be provided).

MODULE 1: Gastrointestinal Cancers 8:05 AM – 8:55 AM

• Patient and disease characteristics guiding therapy for patients with metastatic colorectal cancer (mCRC), including primary tumor location and presence of potentially targetable genetic abnormalities (eg, BRAF, HER2)
• FDA approval of pembrolizumab and nivolumab for patients with MSI-high or mismatch repair-deficient tumors; integration into current mCRC treatment algorithms
• Rational incorporation of regorafenib and TAS-102 into the treatment algorithm for mCRC and early activity and safety data in treatment-refractory gastric cancer
• Integration of ramucirumab into clinical algorithms for metastatic HER2-negative and HER2-positive gastric/gastroesophageal junction (GEJ) cancer
• Ongoing evaluation and current off-protocol role, if any, of FOLFIRINOX or nanoparticle albumin-bound (nab) paclitaxel/gemcitabine for patients with pancreatic adenocarcinoma in the neoadjuvant and adjuvant settings
• Optimal integration of nanoliposomal irinotecan (nal-IRI) into clinical practice
• Recent FDA approval of pembrolizumab for PD-L1-positive recurrent or advanced gastric/GEJ adenocarcinoma after 2 or more lines of chemotherapy and, if appropriate, HER2-targeted therapy; ongoing trials of anti-PD-1/PD-L1 antibodies alone or in combination with other systemic or immunotherapeutic approaches
• Implications for clinical practice of the recent FDA approvals of regorafenib and nivolumab for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib
• Emerging data comparing lenvatinib to sorafenib in patients with advanced, unresectable HCC
• Clinical utility and optimal employment of long-acting somatostatin analogues for neuroendocrine tumors (NETs)
• Current clinical role of everolimus for patients with locally advanced or metastatic, nonfunctional NET of lung or gastrointestinal (GI) origin
• Recent FDA approval of telotristat ethyl for patients with carcinoid syndrome and findings from recent Phase III trials
• Ongoing investigation of other novel agents and strategies in GI cancers (eg, napabucasin, PEGPH20)

MODULE 2: Hodgkin and Non-Hodgkin Lymphomas/
Chronic Lymphocytic Leukemia 8:55 AM – 10:10 AM

• Selection of up-front treatment for chronic lymphocytic leukemia (CLL) in younger and older patients with normal- and high-risk cytogenetics
• Emerging research evidence with and nonprotocol role, if any, of maintenance therapy in CLL
• Practical integration of venetoclax into clinical algorithms; emerging data with use beyond del(17p) disease
• Novel strategies under investigation in CLL (eg, acalabrutinib, ublituximab, anti-PD-1/PD-L1 antibodies)
• FDA approval of subcutaneous rituximab and potential clinical utility
• Efficacy and safety of obinutuzumab-based induction and maintenance therapy for patients with previously untreated follicular lymphoma (FL)
• Available data with and ongoing evaluation of the “R squared” regimen in FL
• Recent FDA accelerated approval of copanlisib for relapsed FL and ongoing investigation of novel agents in FL (eg, ibrutinib, venetoclax, denintuzumab mafodotin)
• Available and emerging research information with novel agents as a component of induction and/or post-transplant maintenance therapy in mantle cell lymphoma (MCL) and treatment options for patients with relapsed/refractory (R/R) disease
• Preliminary outcomes with brentuximab vedotin (BV) as a component of first-line therapy for patients with Hodgkin lymphoma (HL); practical considerations with the use of BV as a bridge to or as consolidation after transplant
• FDA approvals of nivolumab and pembrolizumab for patients with R/R HL; ongoing evaluation of immune checkpoint inhibitors alone or in combination with other immunotherapies or targeted agents in HL
• Available and emerging research information with lenalidomide and ibrutinib in newly diagnosed and R/R diffuse large B-cell lymphoma (DLBCL)
• Emerging research evidence with and potential clinical role of CAR T-cell therapy for patients with DLBCL and other aggressive lymphomas
• Patient- and/or disease-specific factors guiding the sequence and selection of belinostat, pralatrexate and romidepsin in T-cell lymphoma
• Clinical implications and prognostic role of minimal residual disease detection in CLL and various lymphoma subtypes

MODULE 3: Breast Cancer 10:25 AM – 11:15 AM

• Available and emerging data guiding the use of genomic assays to optimize decision-making regarding adjuvant chemotherapy and extended endocrine therapy
• Factors affecting the selection and sequence of systemic therapy for ER-positive metastatic breast cancer (mBC)
• FDA approval of ribociclib and integration of CDK4/6 inhibitors into clinical algorithms for patients with ER-positive mBC
• Recent FDA approval of and Phase III efficacy and safety findings with abemaciclib in ER-positive mBC
• Results and clinical implications of the Phase III APHINITY trial comparing adjuvant chemotherapy/trastuzumab to chemotherapy/trastuzumab/pertuzumab for HER2-positive early BC
• Recent FDA approval of neratinib as extended adjuvant therapy: Patient selection and use in clinical practice
• Ongoing and planned clinical trials incorporating novel HER2-directed therapies in the neoadjuvant and adjuvant settings
• Published data examining the use of combined endocrine and anti-HER2 blockade for triple-positive mBC
• Diagnostic and therapeutic implications of the OlympiAD trial documenting a progression-free survival advantage with olaparib versus chemotherapy for patients with germline BRCA mutation-positive, HER2-negative mBC
• Available data with and ongoing evaluation of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with other systemic agents
• Other novel agents and approaches under investigation for HER2-positive and triple-negative BC

MODULE 4: Ovarian Cancer 11:15 AM – 12:05 PM

• Similarities and differences between available genetic testing platforms; role of extended panel testing/next-generation sequencing
• Identification of “BRCA-like” and other genomic signatures (eg, homologous recombination deficiency) that may predict benefit from PARP inhibition
• Optimal integration of niraparib, olaparib and rucaparib into current ovarian cancer (OC) treatment algorithms; ongoing evaluation of investigational PARP inhibitors
• Clinical role of niraparib and olaparib as maintenance therapy; Phase III study results with maintenance rucaparib
• Recognition and management of PARP inhibitor-related side effects (anemia, GI toxicity, pneumonitis, et cetera)
• Patient selection for neoadjuvant systemic therapy; available data defining the optimal neoadjuvant regimen
• Risks and benefits of intraperitoneal chemotherapy; indications for its use in clinical practice
• Optimal integration of bevacizumab in combination with chemotherapy followed by maintenance bevacizumab into the treatment algorithm for patients with platinum-sensitive recurrent OC
• Mechanism of action of, available efficacy data with and ongoing trials evaluating the role of mirvetuximab soravtansine
• Available safety and efficacy data with and ongoing trials evaluating anti-PD-1/PD-L1 antibodies in patients with OC

MODULE 5: Genitourinary Cancers 12:50 PM – 1:40 PM

• Research database supporting the recent FDA approvals of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab in urothelial bladder cancer (UBC); patient selection for and use of these agents in clinical practice
• Active and planned clinical trials of immune checkpoint inhibitors alone or in combination for early and advanced UBC
• Results of clinical trials evaluating (neo)adjuvant anti-VEGF therapy for unfavorable/high-risk localized or locally advanced renal cell carcinoma (RCC)
• Optimal selection of VEGF-directed therapy for newly diagnosed metastatic RCC (mRCC)
• Current clinical role of nivolumab in advanced RCC; ongoing trials evaluating immune checkpoint inhibitors in RCC
• Clinical experience with cabozantinib and current role in the management of advanced RCC; available data with first-line therapy
• Integration of lenvatinib/everolimus into the care of patients with mRCC
• Investigational approaches with enzalutamide, abiraterone and sipuleucel-T in patients with nonmetastatic castration-resistant prostate cancer (CRPC)
• Available Phase III data with and potential clinical role of adding abiraterone/prednisone to standard hormonal therapy for patients with hormone-sensitive metastatic prostate cancer
• Clinical and biologic factors affecting the sequence and selection of secondary hormonal therapy, immunotherapy and cytotoxic therapy for patients with metastatic CRPC (mCRPC)
• Current indications for radium-223 chloride in clinical practice and rational combination strategies (eg, other bone-targeted or secondary hormonal therapy)
• Incidence of somatic or germline mutations in BRCA1, BRCA2 or ATM in patients with mCRPC; ongoing evaluation of PARP inhibition as a therapeutic strategy

MODULE 6: Lung Cancer 1:40 PM – 2:55 PM

• First-line treatment options for patients with EGFR mutation-positive disease; potential implications of the Phase III FLAURA trial results
• Available efficacy and safety data with osimertinib; effectiveness in patients with CNS metastases
• Selection of first-, second- and later-line therapy for patients with ALK- or ROS1-positive disease; implications of recent data sets and drug approvals
• Recent FDA approval of dabrafenib/trametinib for patients with BRAF V600E tumor mutations
• Potential treatment options for patients with other oncogenic mutations (eg, HER2, MET exon 14, RET, NTRK gene fusions)
• Design, efficacy endpoints and available data from the PACIFIC trial evaluating the use of durvalumab as sequential therapy for patients with locally advanced disease after completion of definitive chemoradiation therapy
• Available data with and patient selection for pembrolizumab with and without chemotherapy in individuals with newly diagnosed metastatic non-small cell lung cancer (NSCLC)
• Ongoing trials of anti-PD-1/PD-L1 antibodies in combination with other immunotherapeutic, chemotherapeutic or targeted approaches
• Selection of first-line therapy for patients with PD-L1-negative squamous NSCLC
• Rational integration of ramucirumab into the management of nonsquamous and squamous NSCLC
• Novel agents under evaluation in small cell lung cancer and malignant pleural mesothelioma

MODULE 7: Acute Leukemias 3:10 PM – 4:00 PM

• Evidence-based induction regimens and postinduction consolidation and/or maintenance therapy for younger/fit patients with acute myeloid leukemia (AML)
• Optimal integration of CPX-351 into the treatment of newly diagnosed therapy-related AML or AML with myelodysplasia-related changes
• Indications for the use of hypomethylating agents as induction and/or maintenance therapy in elderly patients or those with poor-risk AML
• FDA approval of midostaurin for patients with newly diagnosed AML and a FLT3 mutation; patient selection and practical aspects related to its administration
• Mechanisms of action and available research data with the recently FDA-approved IDH1/2 inhibitor enasidenib; ongoing evaluation of novel IDH1/2 (eg, ivosidenib [AG-120]) and FLT3 (eg, gilteritinib, quizartinib) inhibitors in AML
• Recent FDA approval and current clinical role of gemtuzumab ozogamicin for CD33-positive AML
• Other novel agents under evaluation in AML (eg, venetoclax, pracinostat, GMI-1271)
• Selection and sequencing of therapy for patients with Philadelphia chromosome-positive and negative acute lymphoblastic leukemia (ALL)
• FDA approval of CAR T-cell therapy for pediatric and young adult patients with ALL that is refractory or in second or later relapse; ongoing clinical investigation for older adult patients
• Clinical experience with different preparations of asparaginase in young adult and adult patients with ALL
• Patient selection for blinatumomab in ALL clinical practice
• Available research data supporting the recent FDA approval of inotuzumab ozogamicin in R/R B-cell precursor ALL
• Diagnostic considerations for acute promyelocytic leukemia (APL); investigational approaches for low/intermediate-risk disease; choice of induction regimen for patients with high-risk disease